| Project/Area Number |
25460159
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Kyoto Pharmaceutical University |
|---|
Principal Investigator |
Kojima Naoto 京都薬科大学, 薬学部, 准教授 (90420413)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
山下 正行 京都薬科大学, 薬学部, 教授 (20239982)
岩崎 宏樹 京都薬科大学, 薬学部, 助教 (70582592)
|
|---|
| Project Period (FY) |
2013-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 抗がん剤 / 有機合成化学 / 構造活性相関研究 / 生物活性物質 / 構造活性相関 |
|---|
| Outline of Final Research Achievements |
We reported that heterocycle-introduced analogues in the place of lactone ring as a common structure of annonaceous acetogenins, potently inhibit the growth of human cancer cell lines. Especially, a thiophen analog showed potent antitumor activity in in vivo assay using xenograft mice. In this work, we planned to synthesis of dual-core type analogues those have two heterocycles at the both ends of those. As a result, it was revealed that dual-core type analogue shows as potent inhibitory activity as the mother compound, indicating that dual-core type analogues may be a novel lead compound for antitumor agents.
|
